Cencora, Inc., a pharmaceutical distribution company, has recently increased its full-year financial projection due to robust business performance expected for the year. This also includes anticipated contributions from the distribution of the commercial Covid-19 vaccine in the first quarter.
Upon excluding certain factors, Cencora has now raised its predictions for full year earnings per share from the earlier estimate of $12.70 to $13, to a new range of $13.25 to $13.50. Currently, an average of 17 financial market analysts, surveyed by Thomson Reuters, anticipate the company to achieve earnings of $12.91 per share for the entire year, typically disregarding special items.
For the entirety of the year, Cencora now envisions a revenue growth between 10 percent and 12 percent, a rise from the earlier anticipated range of 7 percent to 10 percent. On average, analysts expect Cencora to generate annual revenue of approximately $284.04 billion.
Furthermore, Cencora announced that it will distribute a quarterly cash dividend of $0.51 per share. This is set to be paid out on February 26, to registered shareholders as of February 9.
In the pre-market trading on the New York Stock Exchange, Cencora's stock saw a rise of 3.78 percent, trading at $228.88 per share.
